Related Experiment Video

Updated: Jun 6, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet

Jan Pander1, Henk Jan Guchelaar, Hans Gelderblom

  • 1Leiden University Medical Center, Department of Clinical Oncology, PO Box 9600, 2300RC Leiden, the Netherlands. a.j.gelderblom@lumc.nl

Current Opinion in Molecular Therapeutics
|December 15, 2010
PubMed

Insights

Pharmacogenetic markers in the EGFR gene and drug transporters can predict patient response to tyrosine kinase inhibitors (TKIs). Further validation is needed to personalize cancer treatment using these genetic markers.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Molecular Biology

Background:

  • Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatment by targeting critical growth factor pathways.
  • Unexpected toxicities and variable response rates necessitate predictive markers for TKI therapy.
  • Pharmacogenetic studies investigate germline DNA variations to understand TKI efficacy and toxicity.

Purpose of the Study:

  • To review pharmacogenetic studies on polymorphisms affecting small-molecule TKI response and toxicity.
  • To identify genetic markers associated with treatment outcomes for EGFR-blocking TKIs.
  • To assess the relevance of drug transporter gene polymorphisms in TKI pharmacokinetics.

Main Methods:

  • Review of pharmacogenetic studies utilizing germline DNA.
  • Analysis of polymorphisms in the Epidermal Growth Factor Receptor (EGFR) gene.
  • Investigation of polymorphisms in drug transporting enzymes (ABCB1, ABCG2).

Main Results:

  • EGFR gene polymorphisms (CA-repeat, -216G>T) consistently correlate with response to gefitinib and erlotinib.
  • Polymorphisms in ABCB1 and ABCG2 drug transporters may influence TKI pharmacokinetics, though findings are sometimes conflicting.
  • Evidence suggests a role for genetic variations in predicting TKI treatment outcomes.

Conclusions:

  • Genetic variations in EGFR and drug transporters are potential biomarkers for predicting TKI response.
  • Clinical validation of these pharmacogenetic markers is crucial for individualizing cancer therapy.
  • Further research is needed to successfully implement personalized TKI treatment strategies.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...